Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Purpose of Review Prostate cancer and benign prostate hyperplasia (BPH) are two ubiquitous pathologies that may coexist. A significant percentage of patients with different stages of prostate cancer suffer lower urinary tract symptoms (LUTS) due to associated BPH. We aimed to review the literature regarding the role of transurethral surgeries in the management of prostate cancer patients and the different available management options. Recent Findings The evidence in literature for the use of BPH surgeries in prostate cancer patients is based mainly on low-quality retrospective studies. In patients on active surveillance, BPH surgeries are beneficial in relieving LUTS without oncological risk and can eliminate the contribution of adenoma to PSA level. In patients with advanced prostate cancer, palliative BPH surgery can relieve LUTS and urinary retention with unclear oncological impact; however some reports depict that the need for BPH surgery in advanced prostate cancer is associated with poorer prognosis. In patients receiving radiotherapy, various studies showed that transurethral resection of prostate (TURP) is associated with increased radiotoxicity despite some recent reports encouraging the use of Holmium Laser Enucleation of the Prostate (HoLEP) to improve urinary symptom scores before radiotherapy. The most commonly reported techniques utilized are TURP, photoselective vaporization of prostate (PVP) and HoLEP. Summary The use of BPH surgery is justified for relieving LUTS in selected prostate cancer patients on active surveillance or in advanced stages, however the use in the pre-radiotherapy settings remains controversial. Future prospective and randomized controlled trials are required for validating the benefits and assessing potential hazards.
Purpose of Review Prostate cancer and benign prostate hyperplasia (BPH) are two ubiquitous pathologies that may coexist. A significant percentage of patients with different stages of prostate cancer suffer lower urinary tract symptoms (LUTS) due to associated BPH. We aimed to review the literature regarding the role of transurethral surgeries in the management of prostate cancer patients and the different available management options. Recent Findings The evidence in literature for the use of BPH surgeries in prostate cancer patients is based mainly on low-quality retrospective studies. In patients on active surveillance, BPH surgeries are beneficial in relieving LUTS without oncological risk and can eliminate the contribution of adenoma to PSA level. In patients with advanced prostate cancer, palliative BPH surgery can relieve LUTS and urinary retention with unclear oncological impact; however some reports depict that the need for BPH surgery in advanced prostate cancer is associated with poorer prognosis. In patients receiving radiotherapy, various studies showed that transurethral resection of prostate (TURP) is associated with increased radiotoxicity despite some recent reports encouraging the use of Holmium Laser Enucleation of the Prostate (HoLEP) to improve urinary symptom scores before radiotherapy. The most commonly reported techniques utilized are TURP, photoselective vaporization of prostate (PVP) and HoLEP. Summary The use of BPH surgery is justified for relieving LUTS in selected prostate cancer patients on active surveillance or in advanced stages, however the use in the pre-radiotherapy settings remains controversial. Future prospective and randomized controlled trials are required for validating the benefits and assessing potential hazards.
BACKGROUND Many patients with non-metastatic prostate cancer receive radiotherapy, which may be associated with acute cystitis, particularly if the volume of the urinary bladder is small. Three studies showed bladder volumes <200 ml or <180 ml to be associated with increased urinary toxicity. Therefore, it appears important to achieve bladder volumes >200 ml at as many radiation fractions as possible. Several studies investigated drinking protocols, where patients were asked to drink a certain amount of water prior to radiotherapy sessions. This may require considerable discipline from the mainly elderly patients. Adherence to a drinking protocol may be facilitated by a mobile application (app) that reminds the patients prior to each radiation session to drink water. Our present study investigates the effect of such an app on the filling status of the bladder in prostate cancer patients receiving external beam radiotherapy alone (EBRT). OBJECTIVE The main goal of this study is to evaluate the impact of an app, which reminds patients irradiated for prostate cancer to drink 300 ml of water prior to each radiotherapy session, on the number of fractions with bladder volumes <200 ml during the radiotherapy course. METHODS This phase 2 study is ongoing and requires recruitment of 28 patients treated with EBRT alone for non-metastatic prostate cancer. Radiotherapy will be administered using normo-fractionation with 70-80 Gy in 35-40 fractions of 2.0 Gy, preferably with volumetric-modulated arc therapy (VMAT). Treatment volumes include the prostate with or without the seminal vesicles. A newly developed app will remind the patients to drink 300 ml of water 45 minutes prior to each fraction of radiotherapy. At the end of the radiotherapy course, patients will be asked to complete a questionnaire regarding their satisfaction with the app. In case of a dissatisfaction rate >40%, the app will be considered not useful. Patients will also be asked about the impact of the app on the general use of health technology. In addition, the phase 2 cohort will be matched and compared to a historical control group not supported by an app. The control group is considered appropriate for the comparison, since all patients were treated very recently (in 2022 or 2023) with EBRT alone. RESULTS This trial is the first study that evaluates the impact of a reminder app on the number of radiotherapy fractions with bladder volumes <200 ml in patients irradiated for localized prostate cancer. CONCLUSIONS This study will help identify the potential benefit of a reminder app on the bladder filling status of prostate cancer patients during a course of radiotherapy. CLINICALTRIAL Clinicaltrials.gov NCT06653751; https://clinicaltrials.gov/show/NCT06653751
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.